Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

M. Seike; A. Inoue; S. Sugawara; S. Morita; Y. Hosomi; S. Ikeda; K. Watanabe; K. Takahashi; Y. Fujita; T. Harada; K. Minato; K. Takamura; K. Kobayashi; T. Nukiwa

doi:10.1093/annonc/mdy292.005

Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

M. Seike, A. Inoue, S. Sugawara, S. Morita, Y. Hosomi, S. Ikeda, K. Watanabe, K. Takahashi, Y. Fujita, T. Harada, K. Minato, K. Takamura, K. Kobayashi, T. Nukiwa

MED - Medical Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	viii496
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy292.005
Publication status	Published - 2018 Oct 1

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdy292.005

Cite this

Seike, M., Inoue, A., Sugawara, S., Morita, S., Hosomi, Y., Ikeda, S., Watanabe, K., Takahashi, K., Fujita, Y., Harada, T., Minato, K., Takamura, K., Kobayashi, K., & Nukiwa, T. (2018). Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii496. https://doi.org/10.1093/annonc/mdy292.005

Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). / Seike, M.; Inoue, A.; Sugawara, S. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii496.

Research output: Contribution to journal › Article › peer-review

Seike, M, Inoue, A, Sugawara, S, Morita, S, Hosomi, Y, Ikeda, S, Watanabe, K, Takahashi, K, Fujita, Y, Harada, T, Minato, K, Takamura, K, Kobayashi, K & Nukiwa, T 2018, 'Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii496. https://doi.org/10.1093/annonc/mdy292.005

Seike M, Inoue A, Sugawara S, Morita S, Hosomi Y, Ikeda S et al. Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii496. doi: 10.1093/annonc/mdy292.005

@article{70ab366fb6204592a4f995f250fd7e39,

title = "Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)",

author = "M. Seike and A. Inoue and S. Sugawara and S. Morita and Y. Hosomi and S. Ikeda and K. Watanabe and K. Takahashi and Y. Fujita and T. Harada and K. Minato and K. Takamura and K. Kobayashi and T. Nukiwa",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy292.005",

language = "English",

volume = "29",

pages = "viii496",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

AU - Seike, M.

AU - Inoue, A.

AU - Sugawara, S.

AU - Morita, S.

AU - Hosomi, Y.

AU - Ikeda, S.

AU - Watanabe, K.

AU - Takahashi, K.

AU - Fujita, Y.

AU - Harada, T.

AU - Minato, K.

AU - Takamura, K.

AU - Kobayashi, K.

AU - Nukiwa, T.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85064598888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064598888&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy292.005

DO - 10.1093/annonc/mdy292.005

M3 - Article

C2 - 32137281

SN - 0923-7534

VL - 29

SP - viii496

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this